ArticleMolecular biology of the cell2009
The OGF-OGFr axis utilizes the p16INK4a and p21WAF1/CIP1 pathways to restrict normal cell proliferation.
Article in Molecular biology of the cell, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 43 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
43 citing papers in PubMed, 113 citations in OpenAlex.
- Relationship between expression of OGFR, P16, P21 and clinicopathological features of colorectal cancer patients.Journal, genetic engineering & biotechnology · 2026Article
- Cancer-associated snaR-A noncoding RNA interacts with core splicing machinery and disrupts processing of mRNA subpopulations.Nature communications · 2025Article
- Naltrexone Has Variable and Schedule-Dependent Effects on Oral Squamous Cell Carcinoma Cells.International journal of molecular sciences · 2025Article
- Article
- Loss-of-functionJBMR plus · 2024Article
- Review
- Design, Synthesis, and Antitumor Evaluation of an Opioid Growth Factor Bioconjugate Targeting Pancreatic Ductal Adenocarcinoma.Pharmaceutics · 2024Article
- Elucidating the mechanism of corneal epithelial cell repair: unraveling the impact of growth factors.Frontiers in medicine · 2024Review
- The Opioid Growth Factor in Growth Regulation and Immune Responses in Cancer.Advances in neurobiology · 2024Article
- Elevated Opioid Growth Factor Alters the Limbus in Type 1 Diabetic Rats.Journal of diabetes and clinical research · 2023Article
- Immunomodulatory Role of Neuropeptides in the Cornea.Biomedicines · 2022Review
- Opioidergic Signaling-A Neglected, Yet Potentially Important Player in Atopic Dermatitis.International journal of molecular sciences · 2022Review
- Opioids and Ocular Surface Pathology: A Literature Review of New Treatments Horizons.Journal of clinical medicine · 2022Review
- CIRBP-OGFR axis safeguards against cardiomyocyte apoptosis and cardiotoxicity induced by chemotherapy.International journal of biological sciences · 2022Article
- Ocular surface complications in diabetes: The interrelationship between insulin and enkephalin.Biochemical pharmacology · 2021Review
- Naltrexone as a Novel Therapeutic for Diabetic Corneal Complications.Journal of cellular immunology · 2020Article
- Exogenous OGF enhances the anti-tumor activity of cisplatin on hepatocellular carcinoma.International journal of clinical and experimental pathology · 2019Article
- Long noncoding RNA LINC00673 promotes the proliferation and metastasis of epithelial ovarian cancer by associating with opioid growth factor receptor.OncoTargets and therapy · 2019Article
- Intermittent blockade of OGFr and treatment of autoimmune disorders.Experimental biology and medicine (Maywood, N.J.) · 2018Review
- Integrated Proteomic and Transcriptomic Analysis Reveals Long Noncoding RNA HOX Transcript Antisense Intergenic RNA (HOTAIR) Promotes Hepatocellular Carcinoma Cell Proliferation by Regulating Opioid Growth Factor Receptor (OGFr).Molecular & cellular proteomics : MCP · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Opioid growth factor (OGF) is an endogenous opioid peptide ([Met(5)]enkephalin) that interacts with the OGF receptor (OGFr) and serves as a tonically active negative growth factor in cell proliferation of normal cells. To clarify the mechanism by which OGF inhibits cell replication in normal cells, we investigated the effect of the OGF-OGFr axis on cell cycle activity in human umbilical vein endothelial cells (HUVECs) and human epidermal keratinocytes (NHEKs). OGF markedly depressed cell proliferation of both cell lines by up to 40% of sterile water controls. Peptide treatment induced cyclin-dependent kinase inhibitor (CKI) p16(INK4a) protein expression and p21(WAF1/CIP1) protein expression in HUVECs and NHEKs, but had no effect on p15, p18, p19, or p27 protein expression in either cell type. Inhibition of either p16(INK4a) or p21(WAF1/CIP1) activation by specific siRNAs blocked OGF inhibitory action. Human dermal fibroblasts and mesenchymal stem cells also showed a similar dependence of OGF action on p16(INK4a) and p21(WAF1/CIP1). Collectively, these results indicate that both p16(INK4a) and p21(WAF1/CIP1) are required for the OGF-OGFr axis to inhibit cell proliferation in normal cells.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.